ArticleGynecologic oncology2015
Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study.
Open access · bronzeAbstract readMulticenter Study
In one paragraph
Article in Gynecologic oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer.Cancer causes & control : CCC · 2020Pooled it
- Metabolic syndrome and breast cancer: a dangerous association for postmenopausal women.Acta bio-medica : Atenei Parmensis · 2021Article
- Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations.International journal of molecular sciences · 2021Review
- Association of Anti-Mullerian Hormone, Follicle-Stimulating Hormone, and Inhibin B with Risk of Ovarian Cancer in the Janus Serum Bank.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Article
- Inhibin B suppresses anoikis resistance and migration through the transforming growth factor-β signaling pathway in nasopharyngeal carcinoma.Cancer science · 2018Article
- Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.Oncotarget · 2016Article
- Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer.Oncology letters · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
131 authors at 20 institutions in 11 countries.
Alice W LeeDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Jonathan P TyrerDepartment of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
Jennifer A DohertyDepartment of Epidemiology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
Douglas A StramDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Jolanta KupryjanczykDepartment of Pathology, Institute of Oncology, Warsaw, Poland.
Agnieszka Dansonka-MieszkowskaDepartment of Pathology, Institute of Oncology, Warsaw, Poland.
Joanna Plisiecka-HalasaDepartment of Pathology, Institute of Oncology, Warsaw, Poland.
Beata SpiewankiewiczDepartment of Gynecologic Oncology, Institute of Oncology, Warsaw, Poland.
Emily J MyersDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Australian Cancer Study (Ovarian Cancer)
Australian Ovarian Cancer Study Group
Georgia Chenevix-TrenchCancer Division, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Peter A FaschingUniversity of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology, Los Angeles, CA, USA; University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Universitaetsstrasse 21-23, 91054 Erlangen, Germany.
Matthias W BeckmannUniversity Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Universitaetsstrasse 21-23, 91054 Erlangen, Germany.
Arif B EkiciUniversity Hospital Erlangen, Institute of Human Genetics, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
Alexander HeinUniversity Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen-EMN, Universitaetsstrasse 21-23, 91054 Erlangen, Germany.
Ignace VergoteDivision of Gynecological Oncology, Department of Oncology, University Hospitals Leuven, Belgium.
Els Van NieuwenhuysenDivision of Gynecological Oncology, Department of Oncology, University Hospitals Leuven, Belgium.
Diether LambrechtsVesalius Research Center, VIB, Leuven, Belgium; Laboratory for Translational Genetics, Vesalius Research Center, VIB and KU Leuven, Belgium.
Kristine G WicklundProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Ursula EilberGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.
Shan Wang-GohrkeDepartment of Obstetrics and Gynecology, University of Ulm, Ulm, Germany.
Jenny Chang-ClaudeGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.
Anja RudolphGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.
Lara Sucheston-CampbellDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Kunle OdunsiDepartment of Gynecological Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Kirsten B MoysichDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA.
Yurii B ShvetsovCancer Epidemiology Program, University of Hawaii Cancer Center, HI, USA.
Pamela J ThompsonCancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Marc T GoodmanCancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Lynne R WilkensCancer Epidemiology Program, University of Hawaii Cancer Center, HI, USA.
Thilo DörkGynaecology Research Unit, Hannover Medical School, Hannover, Germany.
Peter HillemannsClinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany.
Matthias DürstDepartment of Gynecology, Jena University Hospital - Friedrich Schiller University, Jena, Germany.
Ingo B RunnebaumDepartment of Gynecology, Jena University Hospital - Friedrich Schiller University, Jena, Germany.
Natalia BogdanovaGynaecology Research Unit, Hannover Medical School, Hannover, Germany.
Liisa M PelttariDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, HUS, Finland.
Heli NevanlinnaDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, HUS, Finland.
Arto LeminenDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, HUS, Finland.
Robert P EdwardsDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Ovarian Cancer Center of Excellence, University of Pittsburgh, Pittsburgh, PA, USA.
Joseph L KelleyDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Philipp HarterDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany; Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany.
Ira SchwaabInstitut für Humangenetik Wiesbaden, Wiesbaden, Germany.
Florian HeitzDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany; Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany.
Andreas du BoisDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany; Department of Gynecology and Gynecologic Oncology, Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany.
Sandra OrsulicWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jenny LesterWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Christine WalshWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Beth Y KarlanWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Estrid HogdallInstitute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark; Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
Susanne K KjaerDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Allan JensenDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Robert A VierkantDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Julie M CunninghamDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Ellen L GoodeDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Brooke L FridleyBiostatistics and Informatics Shared Resource, University of Kansas Medical Center, Kansas City, KS, USA.
Melissa C SoutheyDepartment of Pathology, University of Melbourne, Parkville, VIC Australia.
Graham G GilesCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia.
Fiona BruinsmaCancer Epidemiology Centre, Cancer Council Victoria, Melbourne, VIC, Australia.
Xifeng WuDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michelle A T HildebrandtDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Karen LuDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dong LiangCollege of Pharmacy and Health Sciences, Texas Southern University, Houston, TX, USA.
Maria BisognaGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Douglas A LevineGynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rachel Palmieri WeberDepartment of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA.
Joellen M SchildkrautDepartment of Community and Family Medicine, Duke University Medical Center, Durham, NC, USA; Cancer Control and Population Sciences, Duke Cancer Institute, Durham, NC, USA.
Edwin S IversenDepartment of Statistical Science, Duke University, Durham, NC, USA.
Andrew BerchuckDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC, USA.
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
Daniel W CramerObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA.
Shelley S TworogerDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Elizabeth M PooleDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Sara H OlsonDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Irene OrlowDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elisa V BanderaCancer Prevention and Control, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Line BjorgeDepartment of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
Ingvild L TangenDepartment of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
Helga B SalvesenDepartment of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
Camilla KrakstadDepartment of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway.
Leon F A G MassugerDepartment of Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Lambertus A KiemeneyDepartment for Health Evidence and Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Katja K H AbenDepartment for Health Evidence, Radboud University Medical Centre, Nijmegen, The Netherlands; Comprehensive Cancer Center The Netherlands, Utrecht, The Netherlands.
Anne M van AltenaDepartment of Gynaecology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Yukie BeanDepartment of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA; Knight Cancer Institute, Portland, OR, USA.
Tanja PejovicDepartment of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA; Knight Cancer Institute, Portland, OR, USA.
Melissa KellarDepartment of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA; Knight Cancer Institute, Portland, OR, USA.
Nhu D LeCancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.
Linda S CookDivision of Epidemiology and Biostatistics, Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
Linda E KelemenAlberta Health Services-Cancer Care, Department of Population Health Research, Calgary, AB, Canada; Departments of Medical Genetics and Oncology, University of Calgary, Calgary, AB, Canada.
Angela Brooks-WilsonCanada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC Canada.
Jan LubinskiDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Jacek GronwaldDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Cezary CybulskiDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Anna JakubowskaDepartment of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Louise A BrintonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Jolanta LissowskaDepartment of Cancer Epidemiology and Prevention, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Hannah YangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Lotte NedergaardDeptartment of Pathology, Rigshospitalet, University of Copenhagen, Denmark.
Lene LundvallDepartment of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Claus HogdallDepartment of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Honglin SongDepartment of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
Ian G CampbellDepartment of Pathology, University of Melbourne, Parkville, VIC Australia; Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia.
Diana EcclesWessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.
Rosalind GlasspoolCancer Research UK Clinical Trials Unit, Glasgow, The Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.
Nadeem SiddiquiDepartment of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, UK.
Karen CartyCancer Research UK Clinical Trials Unit, Glasgow, The Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.
James PaulCancer Research UK Clinical Trials Unit, Glasgow, The Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK.
Iain A McNeishInstitute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Beatson Institute for Cancer Research, Glasgow, UK.
Weiva SiehDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
Valerie McGuireDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
Joseph H RothsteinDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
Alice S WhittemoreDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, CA, USA.
John R McLaughlinProsserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Harvey A RischDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.
Catherine M PhelanDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Hoda Anton-CulverDepartment of Epidemiology, Genetic Epidemiology Research Institute, School of Medicine, University of California Irvine, Irvine, CA, USA.
Argyrios ZiogasDepartment of Epidemiology, University of California Irvine, Irvine, CA, USA.
Usha MenonWomen's Cancer, Institute for Women's Health, University College London, London, UK.
Susan J RamusDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Aleksandra Gentry-MaharajWomen's Cancer, Institute for Women's Health, University College London, London, UK.
Patricia HarringtonCentre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
Malcolm C PikeDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Francesmary ModugnoDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Women's Cancer Research Program, Magee-Women's Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Mary Anne RossingProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Roberta B NessThe University of Texas School of Public Health, Houston, TX, USA.
Paul D P PharoahDepartment of Oncology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
Daniel O StramDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Celeste Leigh PearceDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA; Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA. Electronic address: lpearce@umich.edu.
University of Southern California · USCedars-Sinai Medical Center · USUniversity of Copenhagen · DKBrigham and Women's Hospital · USHaukeland University Hospital · NOMemorial Sloan Kettering Cancer Center · USPomeranian Medical University · PLRadboud University Nijmegen · NLStanford University · USUniversity of Cambridge · GBBeatson West of Scotland Cancer Centre · GBDuke Medical Center · USGerman Cancer Research Center · DEHelios Dr. Horst Schmidt Kliniken Wiesbaden · DEInstitute of Psychiatry and Neurology · PLMedizinische Hochschule Hannover · DENational Cancer Institute · USOregon Health & Science University · USRoswell Park Comprehensive Cancer Center · USThe University of Melbourne · AU
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3MHormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5MTRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Chang S Chan · 1997 to 2026
$94.5MUniversity of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Xin Chen · 1996 to 2026
$56.2MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0MRisk Factors for Breast Cancer in Younger NursesR01CA050385 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ELIASSEN, A. HEATHER, WILLETT, WALTER C. · 1989 to 2019
$32.3MNorthern California Cooperative Family Registry for Breast CancerU01CA069417 · NCI · NORTHERN CALIFORNIA CANCER CENTER · PI JOHN, ESTHER M. · 1995 to 2010
$22.4MRPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2013 to 2025
$19.6MUSC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PIKE, MALCOLM C · 1985 to 2009
$18.2MNovel Serum, Plasma, and Urine Biomarkers of Ovarian CanP50CA105009 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2004 to 2010
$13.3MPremonopausal Hormone Levels and Risk of Breast CancerR01CA067262 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HANKINSON, SUSAN E · 2002 to 2011
$11.9MCancer Research UK 10124Cancer Research UK 15960Cancer Research UK 16561Cancer Research UK C490/A10119Cancer Research UK C490/A10124Cancer Research UK C490/A6187CIHR MSH-87734Intramural NIH HHSNCI NIH HHS K07-CA095666NCI NIH HHS K07-CA143047NCI NIH HHS K07-CA80668NCI NIH HHS K22-CA138563NCI NIH HHS N01-CN55424NCI NIH HHS N01-PC035137NCI NIH HHS N01-PC067010NCI NIH HHS N01-PC67001NCI NIH HHS P01-CA017054NCI NIH HHS P01-CA087696NCI NIH HHS P30-CA008748NCI NIH HHS P30 CA071789NCI NIH HHS P30 CA072720NCI NIH HHS P30-CA072720NCI NIH HHS P30-CA15083NCI NIH HHS P50-CA105009NCI NIH HHS P50 CA136393NCI NIH HHS P50-CA136393NCI NIH HHS P50 CA159981NCI NIH HHS P50-CA159981NCI NIH HHS R01-CA014089NCI NIH HHS R01-CA016056NCI NIH HHS R01-CA017054NCI NIH HHS R01-CA049449NCI NIH HHS R01-CA050385NCI NIH HHS R01-CA054419NCI NIH HHS R01-CA058598NCI NIH HHS R01-CA058860NCI NIH HHS R01-CA061107NCI NIH HHS R01-CA061132NCI NIH HHS R01-CA063678NCI NIH HHS R01-CA063682NCI NIH HHS R01-CA067262NCI NIH HHS R01-CA071766NCI NIH HHS R01-CA074850NCI NIH HHS R01-CA080978NCI NIH HHS R01-CA083918NCI NIH HHS R01 CA087538NCI NIH HHS R01-CA087538NCI NIH HHS R01-CA092044NCI NIH HHS R01-CA112523NCI NIH HHS R01-CA114343NCI NIH HHS R01-CA122443NCI NIH HHS R01 CA126841NCI NIH HHS R01-CA126841NCI NIH HHS R01-CA136924NCI NIH HHS R01 CA141154NCI NIH HHS R03 CA113148NCI NIH HHS R03-CA113148NCI NIH HHS R03 CA115195NCI NIH HHS R03-CA115195NCI NIH HHS U01-CA069417NCI NIH HHS U01-CA071966NIEHS NIH HHS T32ES013678
Abstract
objectiveOvarian cancer is a hormone-related disease with a strong genetic basis. However, none of its high-penetrance susceptibility genes and GWAS-identified variants to date are known to be involved in hormonal pathways. Given the hypothesized etiologic role of gonadotropins, an assessment of how variability in genes involved in the gonadotropin signaling pathway impacts disease risk is warranted.
methodsGenetic data from 41 ovarian cancer study sites were pooled and unconditional logistic regression was used to evaluate whether any of the 2185 SNPs from 11 gonadotropin signaling pathway genes was associated with ovarian cancer risk. A burden test using the admixture likelihood (AML) method was also used to evaluate gene-level associations.
resultsWe did not find any genome-wide significant associations between individual SNPs and ovarian cancer risk. However, there was some suggestion of gene-level associations for four gonadotropin signaling pathway genes: INHBB (p=0.045, mucinous), LHCGR (p=0.046, high-grade serous), GNRH (p=0.041, high-grade serous), and FSHB (p=0.036, overall invasive). There was also suggestive evidence for INHA (p=0.060, overall invasive).
conclusionsOvarian cancer studies have limited sample numbers, thus fewer genome-wide susceptibility alleles, with only modest associations, have been identified relative to breast and prostate cancers. We have evaluated the majority of ovarian cancer studies with biological samples, to our knowledge, leaving no opportunity for replication. Using both our understanding of biology and powerful gene-level tests, we have identified four putative ovarian cancer loci near INHBB, LHCGR, GNRH, and FSHB that warrant a second look if larger sample sizes and denser genotype chips become available.
Indexed as
Genetic Predisposition to DiseasePolymorphism, Single NucleotideBiomarkers, TumorCase-Control StudiesFemaleGenetic MarkersGenome-Wide Association StudyGenotypeGonadotropinsHumansLogistic ModelsOvarian NeoplasmsRisk FactorsSignal TransductionBiomarkers, TumorGenetic MarkersGonadotropinsGeneGeneticsGenetic variationGonadotropinsOvarian cancerPolymorphisms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.